HEPATOCELLULAR CARCINOMA AFTER DIRECT ANTIVIRAL AGENTS FOR HEPATITIS C IN PATIENTS WITH DECOMPENSATED CIRRHOSIS
Introduction and Objectives: If direct antiviral agents (DAA) are related to the development of HCC is controversial; therefore, exploring risk factors are crucial. We aimed to determine factors related to the development of hepatocellular carcinoma (HCC) in patients with hepatitis c (HCV) and decom...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-01-01
|
| Series: | Annals of Hepatology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268121003094 |
| _version_ | 1819350244663492608 |
|---|---|
| author | F- Higuera-de-la-Tijera N.C. Flores-García D. Kershenobich E. Cerda-Reyes M.S. González-Huezo J.L. Pérez-Hernández N. Méndez-Sánchez O. Morales-Gutiérrez J.E. Lira-Vera P. Alagón-Fernández-del-Campo F.Y. Vargas-Durán K. Soto-Martínez G.M.L. Guerrero-Avendaño A. Servín-Caamaño J.G. Gándara-Calderón D. García-Domínguez L.E. Díaz-Orozco N. García-Casarreal S. Mejía-Loza I.B. Lázaro-Pacheco E. Rodríguez-Fuentes |
| author_facet | F- Higuera-de-la-Tijera N.C. Flores-García D. Kershenobich E. Cerda-Reyes M.S. González-Huezo J.L. Pérez-Hernández N. Méndez-Sánchez O. Morales-Gutiérrez J.E. Lira-Vera P. Alagón-Fernández-del-Campo F.Y. Vargas-Durán K. Soto-Martínez G.M.L. Guerrero-Avendaño A. Servín-Caamaño J.G. Gándara-Calderón D. García-Domínguez L.E. Díaz-Orozco N. García-Casarreal S. Mejía-Loza I.B. Lázaro-Pacheco E. Rodríguez-Fuentes |
| author_sort | F- Higuera-de-la-Tijera |
| collection | DOAJ |
| description | Introduction and Objectives: If direct antiviral agents (DAA) are related to the development of HCC is controversial; therefore, exploring risk factors are crucial. We aimed to determine factors related to the development of hepatocellular carcinoma (HCC) in patients with hepatitis c (HCV) and decompensated cirrhosis (DC) treated with DAA. Materials and Methods: A multicenter real-world cohort study including patients with HCV + DC treated with sofosbuvir (SOF) based on regimens free of inhibitors of protease (IPs). Results: 222 patients, 118 (53.2%) were women, mean age 57.2 ±11.5-year-old, 209 (94.1%) achieved sustained virological response (SVR). According to Child-Pugh 44(19.8%) were A with history of any clinical decompensation event, 147(66.2%) B, and 31 (14%) C. After DAA, 134 (60.4%) improve in MELD, 45 (20.3%) had no change, and 43 (19.4%) worse, this worse in MELD was related to non-SVR [SVR 37/209 (17.7%) vs. non-SVR 6/13 (46.2%); OR=2.6, 95%CI:1.4-5.0, p=0.02]. Nineteen (8.6%) developed HCC during the follow-up after therapy with DAA; however, when we compared basal laboratory values between those who developed HCC and those who did not only alfa-fetoprotein (AFP) levels were different (without HCC 14.3 [mean 95%CI: 10.6-18.1] ng/mL vs. HCC 55.7 [mean 95%CI: 28.4-83.0] ng/mL; p<0.006). Univariate and multivariate analyses are shown in Table 1. Discussion: Our study confirms that rather than DAA therapy, the most critical factors related to the development of HCC in DC patients with HCV treated with DAA, are non-achieve SVR and, most important basal AFP levels > 20ng/mL, it is essential to note that patients in this cohort had no any suspicious lesion in ultrasonography (USG) previous to start DAA therapy in their semestral screening as most of the guidelines recommend. AASLD, for example, recommends semestral HCC screening with USG with or without AFP, giving more weight to the imagen study. However, based on our results, we recommend always determining AFP levels as a compliment to USG. Conclusions: In HCV patients with DC treated with DAA and with a negative basal screening USG for suspicious malignant lesions, basal AFP > 20ng/mL are the most critical factor related to the development of HCC and should be determined complementary to the USG study.The authors declare that there is no conflict of interest. |
| first_indexed | 2024-12-24T19:13:20Z |
| format | Article |
| id | doaj.art-1e2c0d754dc6415186f74fb1f6d0af70 |
| institution | Directory Open Access Journal |
| issn | 1665-2681 |
| language | English |
| last_indexed | 2024-12-24T19:13:20Z |
| publishDate | 2022-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Annals of Hepatology |
| spelling | doaj.art-1e2c0d754dc6415186f74fb1f6d0af702022-12-21T16:42:57ZengElsevierAnnals of Hepatology1665-26812022-01-0127100607HEPATOCELLULAR CARCINOMA AFTER DIRECT ANTIVIRAL AGENTS FOR HEPATITIS C IN PATIENTS WITH DECOMPENSATED CIRRHOSISF- Higuera-de-la-Tijera0N.C. Flores-García1D. Kershenobich2E. Cerda-Reyes3M.S. González-Huezo4J.L. Pérez-Hernández5N. Méndez-Sánchez6O. Morales-Gutiérrez7J.E. Lira-Vera8P. Alagón-Fernández-del-Campo9F.Y. Vargas-Durán10K. Soto-Martínez11G.M.L. Guerrero-Avendaño12A. Servín-Caamaño13J.G. Gándara-Calderón14D. García-Domínguez15L.E. Díaz-Orozco16N. García-Casarreal17S. Mejía-Loza18I.B. Lázaro-Pacheco19E. Rodríguez-Fuentes20Hospital General de México ''Dr. Eduardo Liceaga''. Ciudad de México, MéxicoInstituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”. Ciudad de México, MéxicoInstituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”. Ciudad de México, MéxicoHospital central militar. Ciudad de México, MéxicoCentro Médico ISSEMyM Metepec, Edo. de México, MéxicoHospital General de México ''Dr. Eduardo Liceaga''. Ciudad de México, México; Hospital Central Sur, PEMEX. Ciudad de México, MéxicoFundación Clínica Médica Sur. Ciudad de México, MéxicoHospital General de México ''Dr. Eduardo Liceaga''. Ciudad de México, MéxicoHospital General de México ''Dr. Eduardo Liceaga''. Ciudad de México, MéxicoHospital General de México ''Dr. Eduardo Liceaga''. Ciudad de México, MéxicoHospital General de México ''Dr. Eduardo Liceaga''. Ciudad de México, MéxicoHospital General de México ''Dr. Eduardo Liceaga''. Ciudad de México, MéxicoHospital General de México ''Dr. Eduardo Liceaga''. Ciudad de México, MéxicoHospital General de México ''Dr. Eduardo Liceaga''. Ciudad de México, MéxicoHospital central militar. Ciudad de México, MéxicoCentro Médico ISSEMyM Metepec, Edo. de México, MéxicoFundación Clínica Médica Sur. Ciudad de México, MéxicoHospital Regional 1° de Octubre, ISSSTE. Ciudad de México, MéxicoHospital Juárez de México. Ciudad de México, MéxicoISSSTE Oaxaca. Oaxaca, MéxicoHospital General de México ''Dr. Eduardo Liceaga''. Ciudad de México, MéxicoIntroduction and Objectives: If direct antiviral agents (DAA) are related to the development of HCC is controversial; therefore, exploring risk factors are crucial. We aimed to determine factors related to the development of hepatocellular carcinoma (HCC) in patients with hepatitis c (HCV) and decompensated cirrhosis (DC) treated with DAA. Materials and Methods: A multicenter real-world cohort study including patients with HCV + DC treated with sofosbuvir (SOF) based on regimens free of inhibitors of protease (IPs). Results: 222 patients, 118 (53.2%) were women, mean age 57.2 ±11.5-year-old, 209 (94.1%) achieved sustained virological response (SVR). According to Child-Pugh 44(19.8%) were A with history of any clinical decompensation event, 147(66.2%) B, and 31 (14%) C. After DAA, 134 (60.4%) improve in MELD, 45 (20.3%) had no change, and 43 (19.4%) worse, this worse in MELD was related to non-SVR [SVR 37/209 (17.7%) vs. non-SVR 6/13 (46.2%); OR=2.6, 95%CI:1.4-5.0, p=0.02]. Nineteen (8.6%) developed HCC during the follow-up after therapy with DAA; however, when we compared basal laboratory values between those who developed HCC and those who did not only alfa-fetoprotein (AFP) levels were different (without HCC 14.3 [mean 95%CI: 10.6-18.1] ng/mL vs. HCC 55.7 [mean 95%CI: 28.4-83.0] ng/mL; p<0.006). Univariate and multivariate analyses are shown in Table 1. Discussion: Our study confirms that rather than DAA therapy, the most critical factors related to the development of HCC in DC patients with HCV treated with DAA, are non-achieve SVR and, most important basal AFP levels > 20ng/mL, it is essential to note that patients in this cohort had no any suspicious lesion in ultrasonography (USG) previous to start DAA therapy in their semestral screening as most of the guidelines recommend. AASLD, for example, recommends semestral HCC screening with USG with or without AFP, giving more weight to the imagen study. However, based on our results, we recommend always determining AFP levels as a compliment to USG. Conclusions: In HCV patients with DC treated with DAA and with a negative basal screening USG for suspicious malignant lesions, basal AFP > 20ng/mL are the most critical factor related to the development of HCC and should be determined complementary to the USG study.The authors declare that there is no conflict of interest.http://www.sciencedirect.com/science/article/pii/S1665268121003094 |
| spellingShingle | F- Higuera-de-la-Tijera N.C. Flores-García D. Kershenobich E. Cerda-Reyes M.S. González-Huezo J.L. Pérez-Hernández N. Méndez-Sánchez O. Morales-Gutiérrez J.E. Lira-Vera P. Alagón-Fernández-del-Campo F.Y. Vargas-Durán K. Soto-Martínez G.M.L. Guerrero-Avendaño A. Servín-Caamaño J.G. Gándara-Calderón D. García-Domínguez L.E. Díaz-Orozco N. García-Casarreal S. Mejía-Loza I.B. Lázaro-Pacheco E. Rodríguez-Fuentes HEPATOCELLULAR CARCINOMA AFTER DIRECT ANTIVIRAL AGENTS FOR HEPATITIS C IN PATIENTS WITH DECOMPENSATED CIRRHOSIS Annals of Hepatology |
| title | HEPATOCELLULAR CARCINOMA AFTER DIRECT ANTIVIRAL AGENTS FOR HEPATITIS C IN PATIENTS WITH DECOMPENSATED CIRRHOSIS |
| title_full | HEPATOCELLULAR CARCINOMA AFTER DIRECT ANTIVIRAL AGENTS FOR HEPATITIS C IN PATIENTS WITH DECOMPENSATED CIRRHOSIS |
| title_fullStr | HEPATOCELLULAR CARCINOMA AFTER DIRECT ANTIVIRAL AGENTS FOR HEPATITIS C IN PATIENTS WITH DECOMPENSATED CIRRHOSIS |
| title_full_unstemmed | HEPATOCELLULAR CARCINOMA AFTER DIRECT ANTIVIRAL AGENTS FOR HEPATITIS C IN PATIENTS WITH DECOMPENSATED CIRRHOSIS |
| title_short | HEPATOCELLULAR CARCINOMA AFTER DIRECT ANTIVIRAL AGENTS FOR HEPATITIS C IN PATIENTS WITH DECOMPENSATED CIRRHOSIS |
| title_sort | hepatocellular carcinoma after direct antiviral agents for hepatitis c in patients with decompensated cirrhosis |
| url | http://www.sciencedirect.com/science/article/pii/S1665268121003094 |
| work_keys_str_mv | AT fhigueradelatijera hepatocellularcarcinomaafterdirectantiviralagentsforhepatitiscinpatientswithdecompensatedcirrhosis AT ncfloresgarcia hepatocellularcarcinomaafterdirectantiviralagentsforhepatitiscinpatientswithdecompensatedcirrhosis AT dkershenobich hepatocellularcarcinomaafterdirectantiviralagentsforhepatitiscinpatientswithdecompensatedcirrhosis AT ecerdareyes hepatocellularcarcinomaafterdirectantiviralagentsforhepatitiscinpatientswithdecompensatedcirrhosis AT msgonzalezhuezo hepatocellularcarcinomaafterdirectantiviralagentsforhepatitiscinpatientswithdecompensatedcirrhosis AT jlperezhernandez hepatocellularcarcinomaafterdirectantiviralagentsforhepatitiscinpatientswithdecompensatedcirrhosis AT nmendezsanchez hepatocellularcarcinomaafterdirectantiviralagentsforhepatitiscinpatientswithdecompensatedcirrhosis AT omoralesgutierrez hepatocellularcarcinomaafterdirectantiviralagentsforhepatitiscinpatientswithdecompensatedcirrhosis AT jeliravera hepatocellularcarcinomaafterdirectantiviralagentsforhepatitiscinpatientswithdecompensatedcirrhosis AT palagonfernandezdelcampo hepatocellularcarcinomaafterdirectantiviralagentsforhepatitiscinpatientswithdecompensatedcirrhosis AT fyvargasduran hepatocellularcarcinomaafterdirectantiviralagentsforhepatitiscinpatientswithdecompensatedcirrhosis AT ksotomartinez hepatocellularcarcinomaafterdirectantiviralagentsforhepatitiscinpatientswithdecompensatedcirrhosis AT gmlguerreroavendano hepatocellularcarcinomaafterdirectantiviralagentsforhepatitiscinpatientswithdecompensatedcirrhosis AT aservincaamano hepatocellularcarcinomaafterdirectantiviralagentsforhepatitiscinpatientswithdecompensatedcirrhosis AT jggandaracalderon hepatocellularcarcinomaafterdirectantiviralagentsforhepatitiscinpatientswithdecompensatedcirrhosis AT dgarciadominguez hepatocellularcarcinomaafterdirectantiviralagentsforhepatitiscinpatientswithdecompensatedcirrhosis AT lediazorozco hepatocellularcarcinomaafterdirectantiviralagentsforhepatitiscinpatientswithdecompensatedcirrhosis AT ngarciacasarreal hepatocellularcarcinomaafterdirectantiviralagentsforhepatitiscinpatientswithdecompensatedcirrhosis AT smejialoza hepatocellularcarcinomaafterdirectantiviralagentsforhepatitiscinpatientswithdecompensatedcirrhosis AT iblazaropacheco hepatocellularcarcinomaafterdirectantiviralagentsforhepatitiscinpatientswithdecompensatedcirrhosis AT erodriguezfuentes hepatocellularcarcinomaafterdirectantiviralagentsforhepatitiscinpatientswithdecompensatedcirrhosis |